Preclinical pharmacology modeling of chimeric antigen receptor T therapies

Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond

(2021) Victor Moreno et al.   CURRENT OPINION IN PHARMACOLOGY

Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B‐cell lymphoma

(2020) Osamu Sakai et al.   Veterinary and Comparative Oncology

The Chimeric Antigen Receptor Detection Toolkit

(2020) Yifei Hu et al.   Frontiers in Immunology

Clinical development of CAR T cell therapy in China: 2020 update

(2020) Jianshu Wei et al.   Cellular & Molecular Immunology

3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids

(2019) Theresa E Schnalzger et al.   EMBO JOURNAL

Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer

(2019) Ye Yao et al.   Cell Stem Cell

A rectal cancer organoid platform to study individual responses to chemoradiation

(2019) Karuna Ganesh et al.   NATURE MEDICINE

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

(2019) Salo N. Ooft et al.   Science Translational Medicine

Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma

(2019) M. Kazim Panjwani et al.   OncoImmunology

Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice

(2019) Hairuo Wen et al.   Annals of Translational Medicine

Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy

(2018) Yue Zhao et al.   GUT

Preclinical Models in Chimeric Antigen Receptor–Engineered T-Cell Therapy

(2018) Elizabeth Louise Siegler et al.   HUMAN GENE THERAPY

Immunotherapy for Gastric Cancer: Time for a Personalized Approach?

(2018) Riccardo Dolcetti et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

OUP accepted manuscript

(2018)   JNCI-Journal of the National Cancer Institute

Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans

(2018) Marco Ruella et al.   MOLECULAR THERAPY

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

(2018) Georgios Vlachogiannis et al.   SCIENCE

Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates

(2018) Agne Taraseviciute et al.   Cancer Discovery

OUP accepted manuscript

(2018)   JNCI-Journal of the National Cancer Institute

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

(2018) Krijn K. Dijkstra et al.   CELL

A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification

(2018) Hanting Zhu et al.   Journal of Thoracic Disease

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues

(2018) Yonghong Li et al.   Engineering

Tumour heterogeneity and resistance to cancer therapies

(2017) Ibiayi Dagogo-Jack et al.   Nature Reviews Clinical Oncology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Experimental animal modeling for immuno-oncology

(2017) Qi-Xiang Li et al.   PHARMACOLOGY & THERAPEUTICS

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors

(2017) Dennis Plenker et al.   Science Translational Medicine

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations

(2017) Katharine Yen et al.   Cancer Discovery

Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells

(2017) Hua Jiang et al.   Protein & Cell

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

(2017) Congcong Zhang et al.   Frontiers in Immunology

Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies

(2016) M. F. Sanmamed et al.   ANNALS OF ONCOLOGY

Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome

(2016) J. M. Pitt et al.   CANCER RESEARCH

Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines

(2016) S. Guo et al.   CANCER RESEARCH

Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility

(2016) Annette Künkele et al.   CLINICAL CANCER RESEARCH

NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors

(2016) Mengmeng Yang et al.   INTERNATIONAL JOURNAL OF CANCER

Prospects for gene-engineered T cell immunotherapy for solid cancers

(2016) Christopher A Klebanoff et al.   NATURE MEDICINE

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

(2016) E. Zah et al.   Cancer Immunology Research

Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

(2016) Aitziber Buqué et al.   OncoImmunology

NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice

(2016) Madhavi Puchalapalli et al.   PLoS One

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein

(2015) H. Qin et al.   BLOOD

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

(2015) Hui Gao et al.   NATURE MEDICINE

Concise Review: Humanized Models of Tumor Immunology in the 21st Century: Convergence of Cancer Research and Tissue Engineering

(2015) Boris Michael Holzapfel et al.   STEM CELLS

A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations

(2015) Dawei Chen et al.   Oncotarget

Differential Role of Th1 and Th2 Cytokines in Autotoxicity Driven by CD19-Specific Second-Generation Chimeric Antigen Receptor T Cells in a Mouse Model

(2014) E. J. Cheadle et al.   JOURNAL OF IMMUNOLOGY

Elimination of Progressive Mammary Cancer by Repeated Administrations of Chimeric Antigen Receptor-Modified T Cells

(2014) Anat Globerson-Levin et al.   MOLECULAR THERAPY

Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells

(2014) C. Berger et al.   Cancer Immunology Research

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma

(2013) Sunitha Kakarla et al.   MOLECULAR THERAPY

CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia

(2013) Marco L. Davila et al.   PLoS One

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy

(2013) Lianhai Zhang et al.   Scientific Reports

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

(2012) H. J. Pegram et al.   BLOOD

T Cells That Target Carcinoembryonic Antigen Eradicate Orthotopic Pancreatic Carcinomas Without Inducing Autoimmune Colitis in Mice

(2012) Markus Chmielewski et al.   GASTROENTEROLOGY

Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients

(2012) Mengmeng Yang et al.   INTERNATIONAL JOURNAL OF CANCER

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

(2012) J. Scholler et al.   Science Translational Medicine

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

(2010) J. N. Kochenderfer et al.   BLOOD

Tumor Ablation by Gene-Modified T Cells in the Absence of Autoimmunity

(2010) L. X. J. Wang et al.   CANCER RESEARCH

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

(2010) Y. Zhao et al.   CANCER RESEARCH

Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells

(2010) Eleanor J. Cheadle et al.   JOURNAL OF IMMUNOLOGY

Genome remodelling in a basal-like breast cancer metastasis and xenograft

(2010) Li Ding et al.   NATURE

Monoclonal antibody-induced cytokine-release syndrome

(2009) Peter J Bugelski et al.   Expert Review of Clinical Immunology

The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway

(2009) Ira Gordon et al.   PLOS MEDICINE